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OBJECTIVE—Glycemic control decreases the incidence and
progression of diabetic complications but increases the inci-
dence of hypoglycemia. Hypoglycemia can impair hormonal and
autonomic responses to subsequent hypoglycemia. Intensive
glycemic control may increase mortality in individuals with type
2 diabetes at high risk for cardiovascular complications. We
tested the hypothesis that prior exposure to hypoglycemia leads
to impaired cardiovascular autonomic function.
RESEARCH DESIGN AND METHODS—Twenty healthy sub-
jects (age 28  2 years; 10 men) participated in two 3-day
inpatient visits, separated by 1–3 months. Autonomic testing was
performed on days 1 and 3 to measure sympathetic, parasympa-
thetic, and baroreﬂex function. A 2-h hyperinsulinemic [hypogly-
cemic (2.8 mmol/l) or euglycemic (5.0 mmol/l)] clamp was
performed in the morning and in the afternoon of day 2.
RESULTS—Comparison of the day 3 autonomic measurements
demonstrated that antecedent hypoglycemia leads to 1) reduced
baroreﬂex sensitivity (16.7  1.8 vs. 13.8  1.4 ms/mmHg, P 
0.03); 2) decreased muscle sympathetic nerve activity response
to transient nitroprusside-induced hypotension (53.3  3.7 vs.
40.1  2.7 bursts/min, P  0.01); and 3) reduced (P  0.001)
plasma norepinephrine response to lower body negative pressure
(3.0  0.3 vs. 2.0  0.2 nmol/l at 40 mmHg).
CONCLUSIONS—Baroreﬂex sensitivity and the sympathetic
response to hypotensive stress are attenuated after antecedent
hypoglycemia. Because impaired autonomic function, including
decreased cardiac vagal baroreﬂex sensitivity, may contribute
directly to mortality in diabetes and cardiovascular disease, our
ﬁndings raise new concerns regarding the consequences of
hypoglycemia. Diabetes 58:360–366, 2009
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ontrol of blood glucose is the cornerstone of
diabetes management because glycemic control
decreases the incidence and progression of di-
abetic microvascular (1–4) and, in some stud-
ies, macrovascular complications (2,5). However, rigorous
glycemic control leads to an increased incidence of hypo-
glycemia (1,6). Even a single episode of hypoglycemia may
impair the counterregulatory metabolic and autonomic
responses to subsequent hypoglycemia (7). Recently, evi-
dence has emerged suggesting an association between
hypoglycemia and increased mortality in critically ill pa-
tients receiving insulin therapy (8). An increase in mortal-
ity was also observed in the highly intensive treated limb
(targeting A1C values of 6%) of a multicenter clinical
trial of individuals with type 2 diabetes at high risk for
cardiovascular disease events (9). The cause of the mor-
tality in these studies could not be directly attributed to
hypoglycemia.
Cardiovascular autonomic impairment is associated
with and may cause increased mortality (10–14). Auto-
nomic neuropathy is a predictor of increased mortality in
many diabetic cohort studies (10,11). In addition, impaired
heart rate variability is associated with increased risk of
mortality in patients after a myocardial infarct (12). More
recent studies in the postmyocardial infarction population
have shown that impaired baroreﬂex sensitivity is an
independent predictor of cardiac mortality (13,14).
In an effort to extend our understanding of the effect of
hypoglycemia on the autonomic nervous system, we tested
the hypothesis that prior exposure to hypoglycemia would
lead to impaired control of cardiovascular autonomic
function. We therefore examined cardiovascular auto-
nomic function using standardized tests measuring sym-
pathetic, parasympathetic, and baroreﬂex function before
and after euglycemic-hyperinsulinemic and hypoglycemic-
hyperinsulinemic clamp studies.
RESEARCH DESIGN AND METHODS
We recruited healthy men and women, aged 18 to 50 years. A complete
medical history, physical examination, and screening autonomic testing were
performed; and blood samples for electrolytes, liver function tests, and
complete blood count were obtained to determine subject eligibility. Each
subject participated in two 3-day inpatient study visits, separated in time by
1–3 months (Fig. 1). On days 1 and 3 of each study visit, subjects underwent
autonomic nervous system testing. On day 2, either two (morning and
afternoon) hypoglycemic-hyperinsulinemic clamp studies or two euglycemic-
hyperinsulinemic clamp studies were performed. Those subjects randomized
to hypoglycemia on the ﬁrst inpatient study visit were exposed to euglycemia
on the second study visit, and vice versa. All autonomic testing was performed
at Beth Israel Deaconess Medical Center by investigational staff unaware of
subject condition, and subjects were transferred by wheelchair and taxi (0.4
Km) to and from Brigham and Women’s Hospital General Clinical Research
Center (GCRC) for overnight stays and day-2 study procedures. The institu-
tional review boards at both institutions approved all study procedures, and
all subjects gave written informed consent.
Diet and activity. Subjects refrained from vigorous exercise for 7 days
before each admission. Subjects consumed an isocaloric diet provided by the
GCRC containing 125  10 mmol/day sodium, 100  10 mmol/day potassium,
and 200  13 mmol/day calcium with water ad libitum for 4 days before study
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360 DIABETES, VOL. 58, FEBRUARY 2009procedures and continuing through to end of day 3. Subjects received a
minimum of 2,000 ml ﬂuid orally on day 2.
Hyperinsulinemic clamp protocols. After completing day 1 autonomic
testing, subjects were admitted to the Brigham and Women’s Hospital GCRC.
After fasting and remaining supine overnight, subjects received a primed,
constant infusion of insulin (160 and 120 mU/m
2 body surface area/min
sequentially for 5 min each, followed by 80 mU/m
2 body surface area/min for
125 min of Novolin R; Novo Nordisk, Princeton, NJ). At t  15, 0, 45, 75, 105,
and 135 min of the insulin infusion, blood was withdrawn for determination of
hormone levels via an indwelling intravenous catheter that was placed in a
retrograde fashion near the wrist of a hand resting in a warm box (66°C).
Blood was withdrawn for glucose determination every 5 min, and the rate of
a 20% dextrose infusion was adjusted to achieve target blood glucose levels of
5.0 mmol/l for the euglycemic clamps and 2.8 mmol/l for the hypoglycemic
clamps. At the end of the 135-min insulin infusion, subjects received a small
snack, and the dextrose infusion rate was adjusted to achieve blood glucose
levels of at least 5.0 mmol/l. After a 90-min break, the hyperinsulinemic clamp
procedure was repeated. Afternoon insulin infusions during hypoglycemic
clamp studies were extended as necessary to achieve 90 min of hypoglycemia.
In four subjects, the insulin infusion was increased by 50% to achieve the
target glucose level of 2.8 mmol/l. On day 2, 24-h urine collections were
obtained. The next morning, subjects returned to Beth Israel Deaconess
Medical Center for the day-3 autonomic testing.
Autonomic testing. Testing was performed at 9:00 A.M. in the autonomic
laboratory of the Beth Israel Deaconess Medical Center on days 1 and 3 of
each study visit. All autonomic investigators were unaware as to whether
subjects had been exposed to hypoglycemia or euglycemia on day 2. Subjects
received a light breakfast 2 h before testing. Subjects were allowed at least a
20-min rest in the supine position in a quiet, dim lit environment to attain
psychological and physiological equilibration before testing. R-R interval,
beat-to-beat blood pressure (Finometer; FMS, Amsterdam, the Netherlands),
and oscillometric blood pressure (Dinamap; Critikon, Tampa, FL) were
measured. Muscle sympathetic nerve activity (MSNA) was recorded from the
peroneal nerve with microneurography. Neural signal was ﬁltered (bandwidth
0.7–2.0 kHz), rectiﬁed, and integrated (time constant, 0.1 s) (Nerve Trafﬁc
Analyzer model 662c-3; University of Iowa Bioengineering, Iowa City, IA).
Sympathetic bursts were identiﬁed by their characteristic morphology and
relationship to R waves on the electrocardiogram using an automated
sympathetic neurogram analysis program (15). The number of sympathetic
bursts was expressed as bursts per minute. The following tests were per-
formed in sequential order.
Paced breathing heart rate variability. The high-frequency region of the
R-R interval power spectrum during supine paced breathing was used to
assess baseline cardiac vagal function. Subjects were instructed to initiate a
breath with each tone of a series of computer generated auditory cues at a
preset, evenly spaced rate of 12 breaths/min. The autospectra of the R-R
interval were estimated for the 7-min segment using the Blackman Tukey’s
method. Power spectral estimates of the R-R interval heart rate were
quantiﬁed using the area (power) of the spectrum in the high-frequency region
(0.15–0.50 Hz) (16).
Baroreﬂex assessment. The modiﬁed Oxford technique was used to assess
cardiac vagal and sympathetic baroreﬂex function (17). After a resting period
of 30 min, a 5-min baseline recording was made followed by the baroreﬂex
test: sequential administration of bolus injections of 100 g sodium nitroprus-
side and of 150 g phenylephrine hydrochloride produced a drop in systolic
blood pressure of 15 mmHg below baseline followed by a rise of 15 mmHg
above baseline. The cardiac vagal baroreﬂex was assessed by the relation
between R-R interval and systolic blood pressure (Fig. 2B). The muscle
sympathetic nerve response to transient hypotension was determined (17).
Simulated orthostatic stress with lower body negative pressure. Graded
lower-body negative pressure (LBNP) was used to simulate orthostatic stress
without the confounding effects of muscle contraction. Supine subjects were
sealed at the waist in a metal tank. After a 5-min baseline data collection
period, pressures of 10, 20, 30, and 40 mmHg were generated sequen-
tially. Four minutes were spent at each negative pressure level. Blood was
drawn for hormone measurements via an indwelling venous catheter at
baseline and after 3 min of each negative pressure level. Subjects rated their
symptoms of lightheadedness, dizziness, weakness, nausea, sweating, and
feelings of impending blackout or fainting on a scale of 0–10 (with 10
indicating the most severe symptom level) using a standardized questionnaire
at minute 3 of each level of LBNP. A score greater than or equal to 3 was
considered a clinically signiﬁcant symptom.
Laboratory tests. Serum insulin levels were measured using the Insulin-
Coat-A Count kit from Diagnostic Products (Los Angeles, CA), with a lower
limit of detection of 18 pmol/l. Serum glucose levels were measured using the
Beckman Glucose Analyzer 2 (Beckman Coulter, Chaska, MN). Plasma
norepinephrine, plasma epinephrine, and 24-h urinary epinephrine levels were
assayed using the 2 CAT RIA kit (Immuno Biological Laboratories, Minneap-
olis, MN). Using the Cortisol Diagnostic Products Coat-A-Count RIA kit, 24-h
urinary collections were assayed for free cortisol levels; and using the Roche
reagent (COBAS Integra 400, Roche Diagnostics, Indianapolis, IN), they were
assayed for creatinine.
Statistical analysis. Data were analyzed using repeated-measures ANOVA
with main effects of treatment (antecedent hypoglycemia and antecedent
euglycemia) and either characteristic points on the cardiac baroreﬂex relation
curve or LBNP level. Nonrepeated measures assessed in two conditions were
analyzed using Student’s two-tailed paired t test. Categorical variables were
compared using Fisher’s exact test. Data are expressed as means  SE.
RESULTS
Demographics, screening, and baseline (day 1) as-
sessments. Twenty healthy subjects (age 28  2 years; 10
men) were studied. Subjects had an average BMI of 24.1 
0.6 kg/m
2, resting heart rate of 64  2 bpm, systolic blood
FIG. 1. Study design. Subjects participated in two, 3-day/2-night protocols separated in time by 1–3 months. Subjects were randomized by
admission to participate in either euglycemic (target blood glucose 5.0 mmol/l)-hyperinsulinemic clamp studies or hypoglycemic (target blood
glucose 2.8 mmol/l)-hyperinsulinemic clamp studies on day 2. Autonomic nervous system (ANS) testing was conducted on days 1 and 3 by
investigators unaware of whether a subject was participating in the euglycemia or hypoglycemia protocol.
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69  2 mmHg at screening. Autonomic testing performed
at screening was within normal limits in all subjects.
Baseline assessments of all autonomic measures were
similar on both of the day 1 studies.
Insulin clamp. Morning baseline levels of glucose (5.3 
0.2 and 5.1  0.1 mmol/l) and insulin (3.9  0.3 and 3.8 
0.4 U/ml) were similar on euglycemic and hypoglycemic
clamp study days, respectively. Serum insulin levels aver-
aged 123  3 U/ml during the clamp studies, with no
signiﬁcant differences between any of the four clamp studies.
Blood glucose averaged 2.8  0.0 mmol/l for the ﬁnal 105 min
of both the morning and afternoon hypoglycemic clamp
procedures and 5.0  0.0 mmol/l for both corresponding
periods of the euglycemic clamps (Fig. 3).
Cortisol and epinephrine were elevated in 24-h urine
collections obtained on the day of the hypoglycemic
clamps compared with levels in urine collections on the
day of the euglycemic clamps, whereas urinary creatinine
levels were similar (Fig. 4). Urine sodium levels were
similar on the euglycemic (119  8 mmol/TV) and hypo-
glycemic (102  7 mmol/TV) clamp study days.
Cardiac vagal and sympathetic baroreﬂex assess-
ment. Cardiac vagal baroreﬂex sensitivity, as determined
by the slope of the relation between R-R interval and blood
pressure during the modiﬁed Oxford test performed on
day 3, was signiﬁcantly reduced after antecedent hypogly-
cemia compared with antecedent euglycemia (Fig. 5A
and B).
Furthermore, to take into account any potential inﬂu-
ence of the variability in baroreﬂex sensitivity between
admissions, we determined the baroreﬂex sensitivity dif-
ference (BRS) (baroreﬂex sensitivity on day 3  barore-
ﬂex sensitivity on day 1 of the same admission). BRS
with antecedent hypoglycemia on day 2 (1.6  4.3
ms/mmHg) was signiﬁcantly less than BRS with anteced-
ent euglycemia on day 2 (2.3  6.3, P  0.01).
Characteristics of the cardiac vagal baroreﬂex function
curve (threshold, mid, and saturation points) are shown in
Table 1 and demonstrate a shift toward the right after
antecedent hypoglycemia compared with antecedent eug-
lycemia. Sympathetic nerve activity during the hypoten-
sive period of the modiﬁed Oxford test was signiﬁcantly
lower after antecedent hypoglycemia compared with an-
tecedent euglycemia (Fig. 5C). There was no association
between BMI, sex, clamp insulin levels, HOMA index, and the
effect of antecedent hypoglycemia on baroreﬂex sensitivity.
Cardiac vagal function during paced breathing. The
R-R interval high-frequency spectral power determined
during paced breathing tended to be lower after the hypogly-
FIG. 2. A: R-R interval (RRint), systolic blood pressure (BP), and muscle sympathetic neurogram (MSNA) recording from a representative subject
during the modiﬁed Oxford procedure. The timing of the nitroprusside and phenylephrine administration is marked by arrows. AIU, arbitrary
integration units. B: The relationship between systolic BP and RRint during the rising portion of the BP trace in this subject is shown. The slope
of the linear portion of the sigmoid curve is the measure of the baroreﬂex sensitivity.
FIG. 3. Serum glucose levels during euglycemic-hyperinsulinemic clamp studies (f) and during hypoglycemic-hyperinsulinemic clamp studies (E).
Arrow indicates target glucose of 5.0 mmol/l for the euglycemia protocol and 2.8 mmol/l for the hypoglycemia protocol.
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103 vs. 804  206 ms
2, P  0.13). There was a positive
correlation between the power spectral density and car-
diac vagal baroreﬂex sensitivity determined after anteced-
ent hypoglycemia (r  0.67, P  0.01) and after antecedent
euglycemia (r  0.57, P  0.05).
Simulated orthostatic stress with LBNP. The R-R
interval and systolic blood pressure at baseline and in
response to increasing levels of LBNP were similar, irre-
spective of whether the study was performed after ante-
cedent hypoglycemia or antecedent euglycemia (Fig. 6A
and B). Plasma norepinephrine levels rose in response to
increasing levels of negative pressure (P  0.0001); how-
ever, this response was signiﬁcantly blunted after anteced-
ent hypoglycemia compared with antecedent euglycemia
(Fig. 6C). Plasma epinephrine levels also increased during
LBNP (P  0.05), but this response was not signiﬁcantly
affected by the antecedent glucose level (Fig. 6D).
In the posteuglycemic condition, a total of 5 of 20 (25%)
subjects experienced clinically signiﬁcant symptoms or
signs of impending syncope, compared with 12 of 20 (60%)
subjects in the posthypoglycemic condition (P  0.05,
Fisher’s exact test).
DISCUSSION
Our data demonstrate that antecedent hypoglycemia re-
sults in a signiﬁcant decrease in 1) cardiac vagal barore-
ﬂex sensitivity and 2) the sympathetic response to both a
transient pharmacologically induced hypotensive stress
and a graded simulated orthostatic stress using LBNP. It is
well established that prior exposure to hypoglycemia
attenuates the autonomic nervous system response to
subsequent hypoglycemia (7,18). The present data, which
show that prior hypoglycemia attenuates the autonomic
response to speciﬁc cardiovascular stresses, extend those
ﬁndings. Furthermore, the evidence that antecedent hypo-
glycemia attenuates cardiovascular autonomic control
may have signiﬁcant clinical implications; impaired auto-
nomic function is associated with and may be a contribu-
tor to mortality in diabetes and cardiovascular disease
(10,12–14).
A B C
FIG. 4. Cortisol (A), epinephrine (B), and creatinine (C) levels in 24-h urines collected on the day of the euglycemic-hyperinsulinemic clamp
studies (f) and hypoglycemic-hyperinsulinemic clamp studies ().
A B C
FIG. 5. A: Baroreﬂex sensitivity after antecedent euglycemic (f) or hypoglycemic (E) clamp studies. B: Change in baroreﬂex sensitivity in
individual subjects after antecedent hypoglycemia versus antecedent euglycemia. C: MSNA assessed at baseline and after nitroprusside in
subjects after antecedent euglycemia (f) or antecedent hypoglycemia (E).
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betic subjects that exposure to recent hypoglycemia re-
duces the counterregulatory hormone (e.g., epinephrine,
glucagon, and adrenocorticotropic hormone) and auto-
nomic nervous system responses to subsequent hypogly-
cemia. This hypoglycemia-associated autonomic failure/
dysfunction leads to decreased ability to sense hypoglycemia
and restore euglycemia (7). However, there are conﬂicting
reports as to whether antecedent hypoglycemia impairs
the autonomic response to nonhypoglycemic stimuli as
well as hypoglycemic stimuli. In one study of type 1
diabetic subjects, the epinephrine and norepinephrine
responses to exercise and upright posture were intact
after antecedent hypoglycemia (19). Other studies of type
1 diabetic subjects suggested that the deﬁcit is more
generalized (20,21); the epinephrine and norepinephrine
responses to a cold pressor test were reduced in well-
controlled type 1 diabetic subjects (20), and antecedent
hypoglycemia reduced the normal exercise-induced rise in
epinephrine, norepinephrine, glucagon, growth hormone,
pancreatic polypeptide, and cortisol in healthy individuals
(21). Our data are consistent with these latter studies and
strongly support the view that the effects of antecedent
hypoglycemia on the autonomic nervous system are more
generalized and not speciﬁc to subsequent hypoglycemic
stimuli.
Prior studies have shown that during hypoglycemia,
there is acquired prolongation of the rate corrected Q-T
interval (22). Our ﬁndings show that antecedent hypogly-
cemia leads to impaired control of cardiovascular func-
tion, even after euglycemia is restored, and that the effects
of antecedent hypoglycemia on autonomic function can
last for at least 16 h. We demonstrated that antecedent
hypoglycemia attenuated the sympathoadrenal and muscle
sympathetic nerve activity outﬂow responses to simulated
orthostatic stress and transient hypotension. Thus, in the
clinical setting, it is possible that recent exposure to
hypoglycemia could impair sympathetic nervous system
responses to cardiovascular stresses.
Antecedent hypoglycemia also decreased baroreﬂex
sensitivity, which indicates impairment in vagal cardiac
modulation. Decreases in vagal autonomic function may
lead to attenuation of vagal protection against sudden
arrhythmic death. Impaired cardiac vagal control, as de-
termined by reduced heart rate variability, is associated
with increased risk of postmyocardial infarction mortality,
even after adjusting for clinical, demographic, other Holter
features, and ejection fraction (12,23–25). In addition,
impairment of baroreﬂex sensitivity has been associated
with adverse outcomes in clinical (13,14) and preclinical
(26) studies.
Baroreﬂex sensitivity, calculated from the measurement
of the heart rate–blood pressure relation after an intrave-
nous bolus of phenylephrine, was a signiﬁcant indepen-
dent risk predictor of cardiac mortality in the Autonomic
Tone and Reﬂexes After Myocardial Infarction (ATRAMI)
study, an international multicenter prospective study of
1,284 patients with a recent myocardial infarction (14).
The 2-year mortality for individuals with baroreﬂex sensi-
tivity 3.1 ms/mmHg was 9%, versus 2% for those with
preserved baroreﬂex sensitivity. In a 5-year follow-up
study of a subset of 244 patients with ST-segment eleva-
tion myocardial infarction and normal ejection fraction,
impaired baroreﬂex sensitivity (3.1 ms/mmHg) 4–6
weeks after the myocardial infarction identiﬁed patients
with a relative risk of cardiovascular mortality of 11.4,
compared with those without impaired baroreﬂex sensi-
tivity (13).
In the current study, baroreﬂex sensitivity in normal
subjects after antecedent hypoglycemia did not reach the
level of 3.1 ms/mmHg; however, given the observed reduc-
tion that was evident in our studies (6 of 20 subjects had a
decrease in baroreﬂex sensitivity of 5 ms/mmHg, and 3
subjects had a decrease in baroreﬂex sensitivity of 10
ms/mmHg), it is possible that similar changes after hypo-
glycemia in individuals impaired baroreﬂex sensitivity at
baseline would lead to baroreﬂex sensitivity 3.1 ms/
TABLE 1
Baroreﬂex function characteristics
After
euglycemia
After
hypoglycemia
Threshold
SBP (mmHg) 120  4 123  4
R-R interval (ms) 790  37 813  33
Midpoint
SBP (mmHg) 127  4 132  3*
R-R interval (ms) 966  39 977  39
Saturation
SBP (mmHg) 134  4 138  3
R-R interval (ms) 1,142  50 1140  47
Baroreﬂex slope (mmHg/ms) 16.7  1.8 13.8  1.4*
Data are means  SE. SBP, systolic blood pressure. *P  0.05.
A BC D
FIG. 6. Effect of antecedent euglycemia and hypoglycemia on RR interval (RRint)( A), systolic blood pressure (BP) (B), norepinephrine (C), and
epinephrine (D) responses to the stimulated orthostatic stress of LBNP. f, measurements obtained after euglycemic-hyperinsulinemic clamp
studies. E, measurements obtained after hypoglycemic-hyperinsulinemic clamp studies. *P < 0.001.
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baroreﬂex sensitivity and/or sympathetic nervous system
cardiovascular control (as noted above) could have clini-
cal implications, especially in critically ill patients or in
patients at high risk for cardiovascular events.
The high-frequency power of the R-R interval in re-
sponse to paced breathing, also an index of cardiac vagal
control, correlated positively with cardiac vagal baroreﬂex
sensitivity in our study. There was a strong tendency
toward a reduction in the high-frequency R-R interval
power in the posthypoglycemic state, but this did not
reach statistical signiﬁcance. Several possible explana-
tions for this ﬁnding exist. These include the following: 1)
The provocation for the cardiac vagal baroreﬂex assess-
ment (transient hypotension) provided a more consistent
and potent stimulus than the provocation for respiratory-
mediated R-R interval variability (we did not monitor or
control the depth of respiration); and 2) there is a differ-
ential effect of hypoglycemia on the autonomic pathways
involved in the two reﬂexes. In future studies, both fre-
quency and amplitude of respiration should be monitored.
The present data may have implications for diabetic
subjects particularly those with autonomic neuropathy
who may have an increased mortality risk (10). Further-
more, it is possible that the consequences of antecedent
hypoglycemia on autonomic function may be ampliﬁed in
diabetic subjects, particularly those with autonomic dys-
function. For example, although the reduced counterregu-
latory and hormonal response to antecedent hypoglycemia
occurs in the absence of diabetic autonomic neuropathy,
as measured by standard tests of autonomic function
(18,27), several (28–30), although not all (22), studies
suggest that the presence of autonomic dysfunction fur-
ther attenuates the autonomic response to hypoglycemia.
Other populations in which the consequences of ante-
cedent hypoglycemia on autonomic function may be more
apparent are critically ill patients and individuals with
diabetes at risk for cardiovascular events. There is a
signiﬁcant increase in mortality in critically ill patients
who experience hypoglycemia. The risk is similar irrespec-
tive of whether the critically ill patients received intensive
or conventional insulin therapy and is not directly caused
by hypoglycemia (8). Similarly, in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study, which
enrolled individuals with diabetes at increased risk of
cardiovascular events, intensively lowering blood glucose
to a goal glycated hemoglobin (A1C) level of 6.0%
increases the risk of death compared with a less intensive
treatment goal of 7.0–7.9% (9). The difference does not
appear to be directly due to hypoglycemia or the use of a
speciﬁc drug. Furthermore, and perhaps of mechanistic
importance, although the relative risk of nonfatal myocar-
dial infarction is lower in the intensively treated group, all
cause mortality and mortality from cardiovascular causes
is greater. The effect of antecedent hypoglycemia on
autonomic cardiovascular function in individuals with
diabetes and in vulnerable diabetic subpopulations, such
as critically ill patients or patients with cardiovascular
disease, is an important area for additional study.
The randomized cross-over design of this study provides
the advantage of each subject serving as his/her own
control. Additionally, subjects were exposed to similar
insulin levels during the hypoglycemic and euglycemic
clamp procedures. However, this trial design also imposed
a potential limitation of residual effects from exposure to
hypoglycemia/euglycemia during the ﬁrst study visit.
Therefore, we reevaluated subjects at least 1 and up to 3
months after the initial study visit. To ensure no interval
change in autonomic function between clamps, baseline
autonomic testing was performed before each clamp.
Furthermore, physical activity and dietary intake (includ-
ing electrolytes) were rigorously controlled.
In summary, these data suggest that cardiovascular
autonomic function, speciﬁcally, baroreﬂex sensitivity and
the sympathetic response to a hypotensive stress, is atten-
uated after antecedent hypoglycemia. Attenuation of
cardiac vagal baroreﬂex sensitivity is an independent
predictor of mortality in postmyocardial infarction pa-
tients. Because our ﬁndings have potential implications for
rigorous glycemic control in diabetes, studies are needed
to determine the effects of antecedent hypoglycemia on
autonomic cardiovascular function in individuals with
type 1 and type 2 diabetes.
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